Bristol Myers Squibb (NYSE:BMY) said it expects to report a Q4 net expense of $18M related to acquired IPRD and licensing ...

Bristol Myers Squibb Co. closed $4.40 below its 52-week high ($61.08), which the company achieved on November 11th.

These seven blue-chip dividend stocks provide investors a steady stream of passive income and offer promising total return.

Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated ...

Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $56.57 which represents a decrease of $-0.22 or -0.39% from the prior close of $56.79. The stock opened at $56.34 and touched a low ...

With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving beyond cancer and rare disease.

Texas Children’s Global HOPE and Baylor College of Medicine Global Health, with support from the Bristol Myers Squibb Foundation, an independent charitable organization, announced the next front in ...

By contrast, the most common Cobenfy side effects in clinical trials were somewhat mild by comparison: nausea, indigestion, constipation, vomiting, hypertension, abdominal pain, diarrhea, increased ...

Explore the recent performance of the SCHD ETF's performance in 2024 and what to expect in the next few months and why it may ...

Topical antifungals, although often effective, are being discouraged in the early treatment of seborrheic dermatitis now that ...

Regeneron Pharmaceuticals is a strong investment with robust growth potential, fueled by FDA approvals and resilient market ...

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...